Modulation of multidrug resistance by verapamil or mdr1 anti‐sense oligodeoxynucleotide does not change the high susceptibility to lymphokine‐activated killers in mdr‐resistant human carcinoma (LoVo) line

Publisher Website
Google Scholar
Abstract
Two sublines were derived from the colon adenocarcinoma line LoVo, the first one was sensitive (LoVo/H) and the second one was made resistant to doxorubicin (LoVo/Dx). When tested for susceptibility to lysis by different types of immune effectors, LoVo/Dx appeared more sensitive than LoVo/H to the killing of CD3+CDS+CD16−, CD3− CD16+‐enriched lymphokine activated killers (LAK) or activated macrophages. In order to check whether this effect was due to different expression of glycoprotein PI70 between the two LoVo sublines (30% vs. 90% of positive cells), a pharmacological and genetic modulation of PI70 was carried out in LoVo cells. Treatment of LoVo/Dx with the calcium channel blocker verpamil (VRP), strongly impaired PI70 function as evaluated by reduced Dx resistance, without affecting the lysability of LoVo/Dx cells by LAKs. Moreover, the significant inhibition of PI70 expression resulting from the treatment of LoVo/Dx with mdrl antisense olideoxynucleotide also failed to change the high lysability of LoVo/Dx by LAKs. These results, therefore, indicate that molecules other than PI70 are involved in the increased lysis of LoVo/Dx subline by immune effectors and that downregulation of the PI70 expression or function will not reduce the potential effectiveness of cancer chemo‐immunotherapy.

This publication has 22 references indexed in Scilit: